Global News | Astellas

Month Year

Jan 30, 2020

Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan

TOKYO and San Francisco, January 30, 2020 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, “FibroGen”) today announced the submission of a supplemental...

Read more about Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan
Jan 23, 2020

AMGEN ASTELLAS BIOPHARMA TO BECOME A WHOLLY OWNED AMGEN AFFILIATE ON APRIL 1, 2020 THE NEW COMPANY NAME WILL BE AMGEN K.K. THE HEADQUARTERS WILL RELOCATE TO TOKYO MIDTOWN

Co-Promotion of Repatha®, EVENITY®, and BLINCYTO® to Continue with Astellas

Amgen Inc. (Headquarters: Thousand Oaks, California, USA; Chairman and CEO: Robert A. Bradway; “Amgen”), Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Kenji Yasukawa, PhD., “Astellas”), and Amgen Astellas BioPharma K.K...

Read more about AMGEN ASTELLAS BIOPHARMA TO BECOME A WHOLLY OWNED AMGEN AFFILIATE ON APRIL 1, 2020 THE NEW COMPANY NAME WILL BE AMGEN K.K. THE HEADQUARTERS WILL RELOCATE TO TOKYO MIDTOWN
Jan 17, 2020

Astellas Announces Construction of New Manufacturing Facility for Active Pharmaceutical Ingredient of Prograf® in Toyama Technology Center

TOKYO, January 17, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the Third Fermentation Building (provisional name) will be constructed as a new manufacturing facility for active pharmaceutical ingredient...

Read more about Astellas Announces Construction of New Manufacturing Facility for Active Pharmaceutical Ingredient of Prograf® in Toyama Technology Center
Jan 15, 2020

Astellas Completes Acquisition of Audentes Therapeutics

- Combined company positioned to become a global leader in AAV-based genetic medicines, with Audentes to operate as a wholly-owned subsidiary and Center of Excellence for Astellas’ newly created Genetic Regulation Primary Focus

TOKYO and San Francisco, January 15, 2020 - Astellas Pharma Inc. (TSE: 4503, President and Chief Executive Officer: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has successfully completed the previously announced acquisition of Audentes Therapeutics...

Read more about Astellas Completes Acquisition of Audentes Therapeutics
Jan 13, 2020

Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

- Agreement covers the co-development and co-commercialization of up to three T-cell therapies -

TOKYO and PHILADELPHIA, PA, OXFORDSHIRE, United Kingdom, January 13, 2020 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas"), through its wholly-owned subsidiary Universal Cells, Inc. and Adaptimmune...

Read more about Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
Jan 6, 2020

Astellas Announces Status of Acquisition of Own Shares

TOKYO, January 6, 2020 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. “the Company”) announced the status of acquisition of its own shares as stated below...

Read more about Astellas Announces Status of Acquisition of Own Shares
Dec 27, 2019

Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.

Acquisition adds talent and proprietary therapeutic platform to accelerate next-generation cancer immunotherapy

TOKYO and SOUTH SAN FRANCISCO, Calif. - December 26, 2019 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Xyphos Biosciences, Inc. (CEO: James...

Read more about Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
Dec 21, 2019

Astellas Announces Production Subsidiary Astellas Pharma Tech Concludes Share Transfer Agreement with CMIC CMO for Succession of Nishine Plant Business

TOKYO, December 21, 2018 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) today announced that Astellas Pharma Tech Co., Ltd. (“Astellas Pharma...

Read more about Astellas Announces Production Subsidiary Astellas Pharma Tech Concludes Share Transfer Agreement with CMIC CMO for Succession of Nishine Plant Business
Dec 17, 2019

XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer

NEW YORK and TOKYO, December 16, 2019 – Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) announced today that the U.S. Food...

Read more about XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer
Dec 16, 2019

Astellas Commences Tender Offer to Acquire All Outstanding Shares of Audentes

TOKYO, December 16, 2019 - Astellas Pharma Inc. (TSE:4503, Headquarters: Tokyo, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that it has commenced, through its...

Read more about Astellas Commences Tender Offer to Acquire All Outstanding Shares of Audentes

Show per page

Choose Language

News